This episode features Paige Twenter, Assistant Editor at Becker's Hospital Review. Here, she discusses the 16 drugs vulnerable to shortages after the closure of US drug company Akorn Operating Co., the coming legal ruling in Texas for the abortion pill, and what is going on with California rescinding $54M deal with Walgreens over abortion pills.
Summary
Becker's Hospital Review assistant editor discusses drugs vulnerable to shortages
Perspective on recent events in the healthcare industry are given by Paige Twenter, Assistant Editor at Becker's Hospital Review.
16 drugs vulnerable to shortages after closure of Akorn Operating Co.
One of the current issues being covered is the recent closure of US drug company, Akorn Operating Co. This has caused concern over the availability of 16 different drugs that the company was producing. One of these drugs is Liquid Albuterol which makes up 100% of the market share in the US and is used in nebulizers for those with difficulty breathing.
Potentially consequential legal ruling in Texas for the abortion pill
Paige is also following the legal ruling for Mifepristone, a medication used for abortion, which has been approved for over 20 years in the US. If the ruling enforces restrictions on access to the pill, it may be withdrawn. This could make it more difficult for those seeking abortions.
California rescinds $54M deal with Walgreens over abortion pills
Walgreens has been involved in a controversy concerning the distribution of abortion pills. After being attacked from both sides for their stance on the issue, Walgreens stated they would only abide by state laws. However, 20 attorneys general threatened legal action, prompting Walgreens to refuse to dispense the pills altogether. As a result, California rescinded a $54 million dollar deal with them, and other states are now consulting with Walgreens' CEO to try and figure out how to progress.
Keeping up to date with the ever-changing healthcare industry
Paige Twenter is keen to provide insight and analysis on current events within the healthcare industry, with an eye on how these developments may impact patients and medical professionals alike.
Note: This is an AI generated transcript, not edited by a staff writer and is solely intended for educational purposes. If you have any questions/concerns, reach out to podcasts@beckershealthcare.com
This episode aired on 03/17/2023 and can be listened here.
Subscribe to Beckers Healthcare Podcast here.